Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of drug interventions for the treatment of sleep disorders in children with autism spectrum disorders: a systematic review

  • Jenabi, Ensiyeh (Pediatric Developmental Disorders Research Center, Hamadan University of Medical Sciences) ;
  • Ataei, Sara (Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences) ;
  • Bashirian, Saeid (Social Determinants of Health Research Center, Hamadan University of Medical Sciences)
  • Received : 2019.06.16
  • Accepted : 2019.09.30
  • Published : 2019.11.15
Download PDF
⟨ Previous Next ⟩

Abstract

A structured review study of drug interventions on sleep disorders in patients with autism spectrum disorders (ASD) has not been published to date. This systematic review aimed to investigate drug interventions for the treatment of sleep disorders in children with ASD. The Web of Science, PubMed, and Scopus databases were searched until March 2019. Study quality was assessed using the Delphi checklist. Due to the heterogeneity of the findings, a meta-analysis was not possible. Drug interventions for the treatment of sleep disorders in patients with ASD included melatonin, atomoxetine, and risperidone. Atomoxetine had no effect on sleep disorders in patients with ASD. A total of 10 studies were reviewed. Melatonin appears to be useful for the treatment of sleep problems in patients with ASD, but further studies are needed to determine the effects of other drugs.

Keywords

References

  1. Maras A, Schroder CM, Malow BA, Findling RL, Breddy J, Nir T, et al. Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Child Adolesc Psychopharmacol 2018 Oct 11 [Epub]. https://doi.org/ 10.1089/cap.2018.0020.
  2. Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011;53:783-92. https://doi.org/10.1111/j.1469-8749.2011.03980.x
  3. Jenabi E, Karami M, Khazaei S, Bashirian S. The association between preeclampsia and autism spectrum disorders among children: a meta-analysis. Korean J Pediatr 2019;62:126-30. https://doi.org/10.3345/kjp.2018.07010
  4. Lyall K, Schmidt RJ, Hertz-Picciotto I. Maternal lifestyle and environmental risk factors for autism spectrum disorders. Int J Epidemiol 2014;43:443-64. https://doi.org/10.1093/ije/dyt282
  5. Chaste P, Leboyer M. Autism risk factors: genes, environment, and gene-environment interactions. Dialogues Clin Neurosci 2012;14: 281-92. https://doi.org/10.31887/DCNS.2012.14.3/pchaste
  6. Hollway JA, Mendoza-Burcham M, Andridge R, Aman MG, Handen B, Arnold LE, et al. Atomoxetine, parent training, and their effects on sleep in youth with autism spectrum disorder and attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2018;28: 130-5. https://doi.org/10.1089/cap.2017.0085
  7. Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res 2012; 21:700-9. https://doi.org/10.1111/j.1365-2869.2012.01021.x
  8. Richdale AL, Schreck KA. Sleep problems in autism spectrum disorders: prevalence, nature, & possible biopsychosocial aetiologies. Sleep Med Rev 2009;13:403-11. https://doi.org/10.1016/j.smrv.2009.02.003
  9. Wright B, Sims D, Smart S, Alwazeer A, Alderson-Day B, Allgar V, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord 2011;41:175-84. https://doi.org/10.1007/s10803-010-1036-5
  10. Devnani PA, Hegde AU. Autism and sleep disorders. J Pediatr Neurosci 2015;10:304-7. https://doi.org/10.4103/1817-1745.174438
  11. Gringras P, Nir T, Breddy J, Frydman-Marom A, Findling RL. Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2017;56:948-57.e4. https://doi.org/10.1016/j.jaac.2017.09.414
  12. Malow BA, Katz T, Reynolds AM, Shui A, Carno M, Connolly HV, et al. Sleep difficulties and medications in children with autism spectrum disorders: a registry study. Pediatrics 2016;137 Suppl 2:S98-104. https://doi.org/10.1542/peds.2015-2851H
  13. Peters JP, Hooft L, Grolman W, Stegeman I. Reporting quality of systematic reviews and meta-analyses of otorhinolaryngologic articles based on the PRISMA statement. PLoS One 2015;10:e0136540. https://doi.org/10.1371/journal.pone.0136540
  14. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998;51:1235-41. https://doi.org/10.1016/S0895-4356(98)00131-0
  15. Wirojanan J, Jacquemont S, Diaz R, Bacalman S, Anders TF, Hagerman RJ, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med 2009;5:145-50. https://doi.org/10.5664/jcsm.27443
  16. Wasdell MB, Jan JE, Bomben MM, Freeman RD, Rietveld WJ, Tai J, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res 2008;44:57-64. https://doi.org/10.1111/j.1600-079X.2007.00528.x
  17. McArthur AJ, Budden SS. Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment. Dev Med Child Neurol 1998; 40:186-92. https://doi.org/10.1111/j.1469-8749.1998.tb15445.x
  18. Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006;32:585-9. https://doi.org/10.1111/j.1365-2214.2006.00616.x
  19. Aman MG, Arnold LE, McDougle CJ, Vitiello B, Scahill L, Davies M, et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 2005;15:869-84. https://doi.org/10.1089/cap.2005.15.869
  20. Relia S, Ekambaram V. Pharmacological approach to sleep disturbances in autism spectrum disorders with psychiatric comorbidities: a literature review. Med Sci (Basel) 2018 Oct 25;6(4). pii: E95. doi: 10.3390/medsci6040095.
  21. Braam W, Smits MG, Didden R, Korzilius H, Van Geijlswijk IM, Curfs LM. Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta-analysis. Dev Med Child Neurol 2009;51:340-9. https://doi.org/10.1111/j.1469-8749.2008.03244.x
  22. Cuomo BM, Vaz S, Lee EAL, Thompson C, Rogerson JM, Falkmer T. Effectiveness of sleep-based interventions for children with autism spectrum disorder: a meta-synthesis. Pharmacotherapy 2017;37:555-78. https://doi.org/10.1002/phar.1920
  23. Guenole F, Godbout R, Nicolas A, Franco P, Claustrat B, Baleyte JM. Melatonin for disordered sleep in individuals with autism spectrum disorders: systematic review and discussion. Sleep Med Rev 2011; 15:379-87. https://doi.org/10.1016/j.smrv.2011.02.001

Cited by

  1. Complementary and Alternative Treatments for Autism Spectrum Disorders: A Review for Parents and Clinicians vol.9, pp.3, 2019, https://doi.org/10.17759/cpse.2020090310
  2. Association between neonatal jaundice and autism spectrum disorders among children: a meta-analysis vol.63, pp.1, 2019, https://doi.org/10.3345/kjp.2019.00815
  3. Neurochemical Mechanisms of Pathogenesis and Pharmacological Correction of Autism Spectrum Disorders: Current Concepts and Prospects vol.15, pp.2, 2019, https://doi.org/10.1134/s1819712421020033
  4. Sleep disorders in attention-deficit hyperactivity disorder and autism spectrum disorder: a pragmatic approach to assessment and management vol.27, pp.5, 2019, https://doi.org/10.1192/bja.2020.65